Peer Network

Welcome to the Peer Network

 

Terms of Use

Index

PLEASE READ THESE TERMS OF USE CAREFULLY. These Terms of Use describe rules for visitors to this United Therapeutics Corporation Web site. This Web site is owned and operated by United Therapeutics Corporation. United Therapeutics Corporation is the name we use to refer to our whole business, including United Therapeutics Corporation, Inc., and any of the companies that it controls, such as its subsidiaries and affiliates. When we use the words we or our, we mean United Therapeutics Corporation. United Therapeutics Corporation also operates other Web sites. These Terms of Use do not apply to our other Web sites. You should review the terms of use posted on these United Therapeutics Corporation Web sites when you visit them.

Please read this page carefully. By using this Web site, you agree to be bound by all of the Terms and Conditions set forth below. If you do not accept these Terms and Conditions, please do not use this Web site.

These Terms of Use were last updated on April 15, 2010. We may change these Terms of Use at any time. Please review the Terms of Use each time you visit the Web site. By using this Web site, it means you accept the most recent version of the Terms of Use.

CALL 911 FOR AN EMERGENCY.

THIS WEB SITE DOES NOT PROVIDE MEDICAL ADVICE. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY.

PEER NETWORK PATIENT-TO-PATIENT PROGRAM GUIDELINES

THE PEER NETWORK IS INTENDED FOR U.S. AUDIENCES ONLY. This PEER Network program and Web site are sponsored by United Therapeutics Corporation. Program participation, product copy and claims are intended only for residents of the United States. Products sold under the same brand names outside of the United States may be subject to different regulatory approvals and standards. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Tyvaso® (treprostinil) Inhalation Solution or Remodulin® (treprostinil) Injection.

All program communication occurs via a secure e-mail system. E-mail communications are meant to be private, one-on-one conversations. United Therapeutics Corporation and/or its agents will not monitor or view e-mail exchanges except as required by law.

To help protect your privacy, we strongly advise program participants to refrain from sharing personally identifiable information (including name, address, phone number, and e-mail) with one another and to utilize the program Web site for all communication.

The information exchanged through the program does not represent medical advice. Seek professional medical advice before initiating any form of treatment. Never disregard medical advice, delay seeking it, or alter, cease, or modify your treatment without first consulting your physician or other health care provider. The opinions of the PEER Mentors are independent and do not necessarily reflect the opinions and policies of United Therapeutics Corporation.

You may opt out of the PEER Network patient-to-patient program at any time, for any reason.

ABOUT THE INFORMATION ON THIS WEB SITE

Much of the information on this Web site relates to products and services offered by United Therapeutics Corporation. The materials on this Web site are for your general educational information only. Information you read on this Web site cannot replace the relationship that you have with your health care professional. United Therapeutics Corporation does not practice medicine or provide medical services or advice and the information on this Web site should not be considered medical advice. You should always talk to your health care professional for diagnosis and treatment.

Health information changes quickly. Therefore, it is always best to confirm information with your health care professional.

This Web site contains information about products and therapies authorized in the United States, and is intended for a United States audience. If you live outside the U.S., you may see information on this Web site about products or therapies that are not available or authorized in your country.

OUR COPYRIGHTS AND TRADEMARKS

The materials on this Web site belong to or are licensed to us. The materials are protected by United States and foreign copyright laws. There are some important rules about copying these materials. You may e-mail, download, or print copies of the materials on this Web site, but only for your personal, noncommercial use. When you e-mail, download, or print a copy of the materials on this Web site, you must also include all copyright and other notices that are in the materials, including the copyright notice on the bottom of the page.

The names, marks, and logos appearing on this site are, unless otherwise noted, trademarks owned by or licensed to United Therapeutics Corporation or an affiliated company. These items are protected by United States and foreign trademark laws. A ® following a name on our Web site indicates that the trademark has been registered in the United States. A ™ following a name on our Web site indicates that it is an unregistered trademark. All trademarks are the property of their respective owners.

There may be special rules for the use of materials provided on certain parts of this Web site. These special rules will be posted near the materials.

If you use the materials or trademarks on this Web site in a way that is not clearly allowed by these Terms of Use, you are violating your agreement with us and may be violating copyright, trademark, and other laws. Any use of our marks contrary to these terms and conditions will result in the automatic revocation of your permission to use this Web site. Title to the materials remains with us or with the authors of the materials contained on this Web site. All rights not expressly granted are reserved.

LINKS TO THIS WEB SITE AND USE OF UNITED THERAPEUTICS CORPORATION MARKS

You are hereby granted a non-exclusive, limited, and revocable license to link to this Web site. United Therapeutics Corporation reserves the right to revoke this license generally, or your right to use specific links, at any time. If United Therapeutics Corporation revokes this license, you agree to remove and disable any and all of your links to this Web site immediately.

You agree not to present the link to this Web site in such a way that it is associated with advertising or appears to be an endorsement of any organization, product, or service. You agree that the link will not appear on a Web site that a reasonable person may consider obscene, defamatory, harassing, grossly offensive, or malicious. Under no circumstances may you "frame" this Web site or any of its content or copy portions of this Web site to a server. You agree not to display or use the United Therapeutics Corporation logo or trademark in any manner without our prior written permission.

LINKS TO OTHER WEBSITES

This Web site may contain links to Web sites not operated by United Therapeutics Corporation. We provide these links for your convenience, but we do not review, control, or monitor the materials on any other Web sites. These Web sites may contain information about uses of United Therapeutics Corporation products or therapies that have not been approved in the United States. We do not control or endorse this type of information. We are not responsible for the performance of those Web sites or for your business dealings with them. Your use of other Web sites is subject to the terms of use of those Web sites, including the privacy policies of those Web sites. If you decide to visit any third-party sites using links from this Web site, you do so at your own risk.

YOUR FEEDBACK, COMMENTS, AND IDEAS

While we are pleased to receive feedback, comments and ideas from visitors to this Web site, we want you to understand that any information that you submit through this Web site will be considered non-personal, non-confidential, and non-proprietary (other than personal information, as that term is defined in our Privacy Statement). If you transmit any ideas, information, concepts, know-how or techniques or materials to us through this Web site, you hereby grant United Therapeutics Corporation an unrestricted, royalty-free, irrevocable license to use, reproduce, display, perform, modify, transmit and distribute them in any medium, and agree that United Therapeutics Corporation is free to use them for any purpose.

As a user of this Web site, you are responsible for your own communications and the consequences of posting them. Therefore, do not do any of the following things: transmit to us material that is copyrighted, unless you are the copyright owner or have the permission of the copyright owner to post it; send material that reveals trade secrets, unless you own them or have the permission of the owner; send material that infringes on any other intellectual property rights of others or on the privacy or publicity rights of others; send material that is obscene, defamatory, threatening, harassing, abusive, hateful, or embarrassing to another user or any other person or entity; send sexually-explicit images; send advertisements or solicitations of business; send chain letters or descriptions of or invitations to participate in pyramid schemes; or impersonate another person. If the company learns or suspects that you may have posted material in violation of these rules, it will remove that material pending further investigation.

If you believe that anything posted on the company's site infringes or may infringe the rights of others, including copyright, please notify Alyssa Friedrich, Senior Vice President, Human Resources & Corporate Development, United Therapeutics Corporation (afriedrich@unither.com). She will investigate your claim and take the appropriate action in response.

LIMITATION OF LIABILITY

Although the company strives for accuracy in all elements of the Site Material, it may contain inaccuracies or typographical errors. Additionally, while users of this Web site are bound by these terms and conditions not to submit false material, the company cannot be responsible for the violation of these terms by users, or for the reliance by users upon false or misleading material submitted by other users. The company makes no representations about the accuracy, reliability, validity, completeness, or timeliness of the material on this Web site or about the results to be obtained from using the Web site or from relying on its material. You use the Web site and its material at your own risk. The site material may not always be the most current source of information, and the company disclaims any duty to update this Web site or the site material, and also disclaims liability for any failure to update this Web site or the site material. In addition, the site material available on this Web site is provided as a convenience only, and where any documents on this Web site have been filed in accordance with applicable securities laws, such documents are not the official versions of the company’s disclosure documents. You are directed to obtain official copies either from applicable securities regulators or from the company.

THE COMPANY DOES NOT WARRANT THAT THE WEB SITE WILL OPERATE ERROR-FREE OR THAT THE WEB SITE AND ITS SERVER ARE FREE OF COMPUTER VIRUSES, WORMS OR OTHER HARMFUL MATERIAL. IF YOUR USE OF THE WEB SITE OR THE SITE'S MATERIAL RESULTS IN ANY COSTS OR EXPENSES, INCLUDING, WITHOUT LIMITATION, THE NEED FOR SERVICING OR REPLACING EQUIPMENT OR DATA, THE COMPANY SHALL NOT BE RESPONSIBLE FOR THOSE COSTS OR EXPENSES. THIS WEB SITE AND ITS MATERIAL ARE PROVIDED ON AN "AS IS" BASIS WITHOUT ANY WARRANTIES OF ANY KIND. TO THE FULLEST EXTENT PERMITTED BY LAW, THE COMPANY DISCLAIMS ALL WARRANTIES, INCLUDING WITHOUT LIMITATION THE WARRANTY OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES' RIGHTS, AND THE WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. ALTHOUGH THE COMPANY STRIVES TO PROVIDE THOROUGH AND ACCURATE MATERIALS ON ITS SITE, WE MAKE NO WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS, OR TIMELINESS OF THE MATERIAL, SERVICES, SOFTWARE, TEXT, GRAPHICS, AND LINKS.

Disclaimer of Damages

IN NO EVENT SHALL THE COMPANY, ITS AFFILIATES, OR ANY THIRD PARTIES MENTIONED ON THE SITE BE LIABLE FOR ANY DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE OR EXEMPLARY DAMAGES, LOST PROFITS, OR DAMAGES RESULTING FROM LOST DATA OR BUSINESS INTERRUPTION) RESULTING FROM THE USE OR INABILITY TO USE MATERIAL ON THIS WEB SITE OR SITES LINKED TO THIS WEB SITE, WHETHER BASED ON WARRANTY, CONTRACT, TORT, OR ANY OTHER LEGAL THEORY, AND WHETHER OR NOT THE COMPANY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

Indemnity

By using this Web site, you agree to defend, indemnify, and hold harmless the company, its officers, directors, employees and agents from and against any and all losses, claims, damages, costs and expenses (including reasonable legal and accounting fees) that the company may become obligated to pay arising or resulting from your use of the site material or your breach of these Terms and Conditions. The company reserves the right to assume or participate, at your expense, in the investigation, settlement and defense of any such action or claim.

OTHER RULES ABOUT THIS WEB SITE

In addition to the rules in these Terms of Use and the Privacy Statement, you may be subject to additional terms that may apply when you access particular services or materials on certain areas in this Web site, such as when you purchase enhanced services, or by following a link from this Web site. Please read our Privacy Statement to learn how we protect and use information that we gather through this Web site.

Your obligations under this section and the sections called "Your Feedback", "No Warranties" and "Limitation of Liability" will survive termination of these Terms of Use.

If any provision of these Terms of Use is found to be invalid by any court having competent jurisdiction, the invalidity of such provision shall not affect the validity of the remaining provisions of these Terms of Use, which shall remain in full force and effect. No waiver of any of these Terms of Use shall be deemed a further or continuing waiver of such term or condition or any other term or condition.

If you violate these Terms of Use or the Privacy Statement in a way that causes harm to others, you agree to hold United Therapeutics Corporation harmless against any liability for that harm.

By using this Web site, you agree that the only proper jurisdiction and venue for any dispute with United Therapeutics Corporation, or in any way relating to your use of this Web site, is in the state and federal courts in the State of Maryland, U.S.A. You further agree and consent to the exercise of personal jurisdiction in these courts in connection with any dispute involving United Therapeutics Corporation or its affiliates, employees, officers, directors, agents, or suppliers.

These Terms of Use are governed by the internal substantive laws of the State of Maryland, without respect to its conflict of laws principles, and the federal laws of the United States.

All questions about Privacy are addressed by the Privacy Statement.

QUESTIONS, COMMENTS, AND NOTICES

United Therapeutics Corporation may deliver notice to you by electronic mail, a general notice on this Web site, or by written communication delivered by First Class U.S. Mail to your address on record with United Therapeutics Corporation. You may deliver notice to United Therapeutics Corporation by using the Contact United Therapeutics Corporation feature, or at:

United Therapeutics Corporation
1110 Spring St.
Silver Spring, MD 20910

THE PEER NETWORK IS INTENDED FOR U.S. AUDIENCES ONLY. This PEER Network program and Web site are sponsored by United Therapeutics Corporation. Program participation, product copy and claims are intended only for residents of the United States. Products sold under the same brand names outside of the United States may be subject to different regulatory approvals and standards. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Tyvaso® (treprostinil) Inhalation Solution or Remodulin® (treprostinil) Injection.

Reporting Adverse Events
Please note that this Web site does not collect or report adverse events. If you are taking Tyvaso or Remodulin and have experienced or are experiencing a potential adverse event, please inform your healthcare provider.

Tyvaso® (treprostinil) Inhalation Solution

INDICATION
Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase-5 inhibitor). The effects decrease over 4 hours; treatment timing can be adjusted for planned activities.

Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

IMPORTANT SAFETY INFORMATION for Tyvaso

  • Tyvaso is breathed in (inhaled) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.
  • The effects of Tyvaso are unknown in patients with lung disease (such as asthma or chronic obstructive pulmonary disease) and in patients under 18 years of age.
  • If you have low blood pressure, Tyvaso may cause symptomatic hypotension (low blood pressure).
  • Because Tyvaso reduces the ability of your blood to clot (coagulate), it may increase your risk for bleeding if you are taking blood thinners (anticoagulants), such as warfarin or heparin.
  • The use of Tyvaso with diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure) may increase your risk for hypotension (low blood pressure).

Other medical conditions and medicines may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking, including:

  • If you are taking gemfibrozil (for high cholesterol) or rifampin (for infection), your Tyvaso dosage may need adjustment.
  • If you have liver or kidney problems, your ability to tolerate Tyvaso may be affected.
  • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your healthcare provider about whether you should take Tyvaso.

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your doctor about any side effects that bother you or do not go away. Your doctor may be able to help you manage the side effects.

For additional information about Tyvaso, please see accompanying Full Prescribing Information, Patient Package Insert and the Tyvaso Inhalation System Instructions for Use manual, visit www.tyvaso.com, or call 1-877-864-8437.

Remodulin® (treprostinil) Injection

INDICATION
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

In patients with PAH requiring transition from Flolan® (epoprostenol sodium), Remodulin is indicated to diminish the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.

IMPORTANT SAFETY INFORMATION for Remodulin

  • Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Therefore, continuous subcutaneous infusion is the preferred mode of administration.
  • Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.
  • Remodulin is a potent pulmonary and systemic vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure.
  • Remodulin inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants.
  • Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
  • Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care.
  • Therapy with Remodulin may be used for prolonged periods, and the patient’s ability to administer Remodulin and care for an infusion system should be carefully considered.
  • Remodulin dosage should be increased for lack of improvement in, or worsening of, symptoms and it should be decreased for excessive pharmacologic effects or for unacceptable infusion site symptoms.
  • Abrupt withdrawal or sudden large reductions in dosage of Remodulin may result in worsening of PAH symptoms and should be avoided.
  • Caution should be used in patients with hepatic or renal insufficiency.
  • The most common side effects of Remodulin included those related to the method of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and swelling) occurred in the majority of patients. These symptoms were often severe and could lead to treatment with narcotics or discontinuation of Remodulin. For intravenous infusion, line infections, sepsis, arm swelling, tingling sensations, bruising, and pain were most common. General side effects (>5% more than placebo) were diarrhea, jaw pain, vasodilatation and edema.

For additional information about Remodulin, please see the Full Prescribing information, visit http://www.remodulin.com, or call 1-877-864-8437.